AnaptysBio price target lowered to $52 from $55 at H.C. Wainwright
The Fly

AnaptysBio price target lowered to $52 from $55 at H.C. Wainwright

H.C. Wainwright lowered the firm’s price target on AnaptysBio (ANAB) to $52 from $55 and keeps a Buy rating on the shares following the Q3 report. The firm says that despite Lilly discontinuing peresolimab, it remains confident in AnaptysBio’s Phase 2 rheumatoid arthritis data expected in February 2025.

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App